Ultra-Rare Gene-Based Therapy (URGenT) Network
Department of Health and Human Services ▸ National Institutes of Health ▸
Description
This grant opportunity aims to support projects that speed up the development of a strong clinical candidate with solid scientific evidence and proven success in a relevant model system for a specific patient group. The ultimate goal is to reach the stage of filing an Investigational New Drug (IND) application and starting a clinical trial.
The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an…
Source
Grant ID
PAR-25-327
Funding Source
Department of Health and Human Services ▸ National Institutes of Health ▸
Key Dates
Opportunity Released
December 18, 2024
Eligibility
The following categories of applicants are invited to apply:
- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education
- Nonprofit Organizations with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofit Organizations without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- For-Profit Organizations (Other than Small Businesses)
- Small Businesses
- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Local Governments (General)
- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Eligible Agencies of the Federal Government
- U.S. Territories or Possessions
- Faith-based Organizations
- Community-based Organizations
- Regional Organizations
Similar opportunities
- Notice of Funding Opportunity for Rare Disease Therapeutic Development
- Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
- Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics): Biologics-based Therapy Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
- Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
- NINDS Ultra-Rare Gene-based Therapy (URGenT) Network